2022年11月8日

2022年11月8日美國東部標準時間上午08:00瑞士波士頓和巴塞爾——(美國商業資訊)——計算精確醫學公司Genialis本周將展示其生物標誌物發現平台ResponderIDTM的新數據和結果。在癌症免疫治療學會(SITC)年會上，Genialis首席發現官Luka Ausec博士與Exact Sciences和oncener Therapeutics聯合發布了一篇名為“Xerna腫瘤微環境亞型作為肺癌患者的生物標誌物”的海報。XernaTM TME麵板是一種新型的基於基因表達的生物標誌物，可幫助確定疾病亞型，並為許多實體腫瘤提供治療方案。這篇海報探討了Xerna TME亞型和NSCLC中基於dna(例如基因變異)的生物標誌物之間的關係。同樣在本周，Genialis首席執行官Rafael Rosengarten博士將出席BiotechX(巴塞爾)，介紹使ResponderID生物標記物成功的獨特方法和技術創新。2022年，ResponderID生成的結果在包括AACR、ESMO和SITC在內的主要科學會議上以海報形式展示。Genialis還在《臨床腫瘤學雜誌》上合著了一篇論文，描述了onxerna的navicixizumab ph1b試驗，包括與Xerna TME小組的回顧性分析。ResponderID平台是一套用於臨床和轉化研究的技術套件，由多年與整個行業的合作夥伴和先進的內部研發合作經驗構建而成。ResponderID為藥物開發和發現項目定義、建模和驗證新的生物標誌物。ResponderID可以從單個檢測中讀取幾乎任何基於ngs的生物標誌物的狀態，包括定製的和專有的簽名。 The resulting output provides clinical and translational researchers with a comprehensive molecular portrait of their patients, yielding the most informed decision-making possible. “Genialis and its collaborators continue to generate evidence of the broad applicability of ResponderID derived biomarkers. We’ve shared much of this progress with the scientific and clinical communities at numerous conferences this year,” said Rafael Rosengarten, Ph.D., CEO of Genialis. “Our goal is to develop biomarkers that help as many patients as possible get the best therapy for their disease. That means disseminating the validation of our models widely.” At BiotechX, Dr. Rosengarten will also participate in a panel discussion with fellow executive officers from the Alliance for Artificial Intelligence in Healthcare. Genialis' role on the executive committee and board of the AAIH positions it as a peer among global leaders in applying machining learning to drug development. To request a meeting at SITC or BioTechX, or for more information on ResponderID, please email info@genialis.com or visit www.genialis.com . About Genialis Genialis is a computational precision medicine company unraveling complex biology to find new ways to address disease. ResponderID™, Genialis’ clinical biomarker discovery platform, defines, models, and validates actionable biomarkers and optimally positions novel drugs to accelerate translational research and clinical development. Genialis is trusted by biopharma and big pharma alike, and together, we bring precision to medicine. Contacts